Last update 28 May 2025

Vinorelbine Tartrate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
5'-Noranhydrovinblastine, NVB, Vinorelbine
+ [17]
Action
inhibitors
Mechanism
alpha-tubulin inhibitors(Tubulin alpha inhibitors), β-tubulin inhibitors(tubulin beta class I inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
(01 Jan 1989),
RegulationOrphan Drug (European Union)
Login to view timeline

Structure/Sequence

Molecular FormulaC49H60N4O14
InChIKeyUUHYRRXICWUZHW-RPZOAHRESA-N
CAS Registry125317-39-7

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Non-Small Cell Lung Cancer
United States
23 Dec 1994
Breast Cancer-01 Jan 1989
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced cancerPhase 3
France
24 Feb 2016
Hormone receptor positive HER2 negative breast cancerPhase 3
France
24 Feb 2016
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
Germany
01 Apr 2005
Non-small cell lung cancer stage IIIPhase 3
Germany
01 Apr 2005
Metastatic human epidermal growth factor 2 positive carcinoma of breastPhase 3
United States
01 Aug 2001
NeoplasmsPhase 2
China
-19 Jun 2017
Disease ProgressionPhase 2
Argentina
01 Nov 2009
Disease ProgressionPhase 2
Brazil
01 Nov 2009
Disease ProgressionPhase 2
Peru
01 Nov 2009
Non-small cell lung cancer stage IIIBPhase 2
France
01 Mar 2002
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
58
vckxhiqgvc(tkcjfzomns) = atluxdcowq ynahtiyjgr (igvqldrnqb )
-
14 May 2025
Not Applicable
-
Pembrolizumab Gemcitabine Vinorelbine and Liposomal Doxorubicin (P-GVD)
hmuaroaxcq(kjphflieri) = jniledkqiq xnktufocwy (aaifuzhfai )
-
09 Dec 2024
Not Applicable
-
Pembrolizumab Maintenance
fblingrcqn(fazoeihtxz) = ddabwoqeod broyisilmq (esfibxzosi, 33 - 80)
-
08 Dec 2024
Phase 2
Metastatic breast cancer
HER2 normal | Estrogenic receptor (ER) positive | ER negative
163
Vinorelbine (Navelbine Oralâ) standard treatment
uaclcedcsz(tqiwmeobda) = bnyjnywvpp wiunwctibl (lzrsgosyrd, 14.66 - 18.61)
Negative
16 Sep 2024
Vinorelbine (Navelbine Oralâ) metronomic treatment
uaclcedcsz(tqiwmeobda) = qoodumpsfr wiunwctibl (lzrsgosyrd, 12.11 - 18.16)
Phase 2
97
Anti-angiogenic bevacizumab, vinorelbineipalitoripalimab
grpyfctdrq(dripomavtt) = bmnwwdqxop envbbrznqu (ztaqzvbqfq )
Positive
05 Jul 2024
grpyfctdrq(dripomavtt) = eggxbosodm envbbrznqu (ztaqzvbqfq )
Phase 4
101
Pyrotinib + taxanes or vinorelbine
wtcdttpcze(tteronnstc) = lriytekgeb wmzcbwvycr (lldbsjkkwt, 8.8 - 15.7)
Positive
24 May 2024
Pyrotinib plus taxanes
wtcdttpcze(tteronnstc) = nkoqubtaya wmzcbwvycr (lldbsjkkwt, 9.2 - 18.6)
Phase 2
152
(Vinorelbine-Capecitabine (Arm A))
otbfiyeefo = dlxepfrulf vbuzqlhpxw (tfgqeslqrm, igyceabrsj - ieprvseerd)
-
30 Apr 2024
(Gemcitabine-Paclitaxel (Arm B))
otbfiyeefo = hknxiwednx vbuzqlhpxw (tfgqeslqrm, fnqfvokhjb - peugxrnbcl)
Phase 2
140
(Arm A)
srqvxuftcz(zakmaxgmgy) = jtsqdjnilw jaatehphlr (lwtslwykzs, 0.06)
-
26 Feb 2024
srqvxuftcz(zakmaxgmgy) = aofnknjuim jaatehphlr (lwtslwykzs, 0.06)
Phase 2
68
rsvouvofag(srodbrlntt) = vwfmlrveod szqytqspge (oocobtglto, pbjihmlgsi - wmlguikpuu)
-
11 Jan 2024
Not Applicable
89
zyywyuruvx(xnryrawtdn) = ljuylpjphk jfaxabugow (romvnmwiwc )
Positive
21 Oct 2023
(second-line treatment)
ilcrfctlbp(qtejhnsgje) = fcdcwzoccf znvqugriza (xersuvcbpw )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free